LIVALO R Demonstrates Sustained, Long-Term Efficacy And Tolerability In Patients With Valuable Hypercholesterolemia Or Mixed Dyslipidemia
New data presented showed that in patients treated with LIVALO (pitavastatin), high-density lipoprotein cholesterol (HDL-C) concentrations increased, and nearly three-fourths of patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results sustained over 52 weeks. Additionally, LIVALO was found to annex analogous efficacy to atorvastatin and simvastatin, as measured by lessening in LDL-C from baseline. The Period III data were presented at the European Society of Cardiology Congress (ESC) in Barcelona, Spain. "These studies confirm that the efficacy of LIVALO is comparable to other commonly used statins, and that it is an adequate and chipper tolerated long-term treatment choice for patients, " said Leiv Ose, M.
Nearly half (48%) of statin-treated patients are not assignation target levels of low-density lipoprotein cholesterol (LDL-C), according to the results of a brand-new international study, conducted by Merck Sharp & Dohme Limited and presented nowadays at the European Society of Cardiology (ESC) congress in Barcelona, Spain.1 Additionally, almost three-quarters (73%) of the same patients had at least one lipid abnormality across LDL-C, HDL-C and triglyceride levels.1 In a seperate UK survey, results hog besides shown a want for improving education of the accepted around how to proactively handle their lipid levels.2 The DYSlipidemia International Recite (DYSIS) was a great interpret involving 22, 000 statin-treated patients, extending across 12 countries in Europe and Canada.
According to a au courant review of 22, 000 patients, almost three-quarters of patients beguiling statins still had at least one lipid abnormality. These results, from a discover conducted by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., which operates in innumerable countries as Merck Sharp & Dohme Limited, were presented at the European Society of Cardiology (ESC) congress in Barcelona, Spain. The DYSlipidemia International Interpret (DYSIS) assessed the prevalence of dyslipidemia among patients taking statins by measuring LDL-cholesterol (LDL-C or "bad" cholesterol ), HDL-cholesterol (HDL-C or "good" cholesterol), and triglyceride (TG) levels of deeper than 22, 000 patients aged 45 and older who had received statin therapy for at least three months.
Got alpine cholesterol? You might require to accede a bone density test. A dissimilar UCLA glance at sheds bright on the link between big cholesterol and osteoporosis and identifies a different way that the body's proof cells play a role in bone loss. Published Aug. 20 in the notebook Clinical Immunology, the research could cause to current immune-based approaches for treating osteoporosis. Affecting 10 million Americans, the disease causes fragile bones and increases the risk of fractures, resulting in disoriented independence and mobility. Scientists have high recognized the relationship between elevated cholesterol and osteoporosis, but pinpointing the exact mechanism connecting the two has proved elusive.
CVS Caremark Info Finds More Than 50 Percent Of Adults 45 Elderliness And Younger Are Not Adherent To Cholesterol Lowering Medications
A glance at released nowadays by CVS Caremark (NYSE: CVS) found that expanded than 50 percent of patients under the age of 45 who are prescribed a medication to treat big cholesterol are not optimally adherent to their therapy. In fact, the data showed that 58 percent of adults between the ages of 18-34 are not taking their cholesterol lowering medications as prescribed. According to the Public Institutes of Health's Governmental Heart, Lung and Blood Institute (NHLBI), alpine cholesterol affects and than 65 million Americans. Because aerial cholesterol does not end symptoms, individuals may not be aware that they are at increased risk of developing feelings disease or experiencing a heart attack.
A minor molecule earlier commence to hold both anti-fat and anti-cancer abilities works as a literal turnoff for fat-making genes, according to a inexperienced report in the August 28th nut of the journal Chemistry and Biology, a Cell Press journal. The chemical blocks a hale known master controller of fat synthesis, a transcription part known as SREBP. That animation in mice that are genetically prone to obesity causes the animals to develop into leaner. It further lowers the amount of fat in their livers, along with their blood sugar and cholesterol levels. "We are frankly too aflame approximately it, " said Salih Wakil of Baylor College of Medicine. "It goes to the origin of [fat synthesis] - all the way back to gene expression.
Health-conscious people comprehend that high levels of complete cholesterol and LDL cholesterol (the so-called "bad" cholesterol) can increase the risk of heart attacks. Now scientists are reporting that another conformation of cholesterol called oxycholesterol - practically little known to the public - may be the most grim cardiovascular health threat of all. Scientists from China presented one of the front studies on the cholesterol-boosting baggage of oxycholesterol t the 238th Federal Assemblage of the American Chemical Society. The researchers concern their findings raise public awareness approximately oxycholesterol, including foods with the highest levels of the substance and other foods that can combat oxycholesterol's effects.
Cholesterol can affect the flow of the electrical currents that generate the emotions beat, according to a study from two UBC cardiovascular researchers funded by the Passion and Stroke Foundation of BC & Yukon. The check team has just published the conspicuous discovery approximately the causes of cardiac arrhythmias (abnormal heartbeats) in one of the world's essential scientific journals. Together with a battery from Paris, France, UBC researchers David Fedida and Jodene Eldstrom found that extremely all the more cholesterol can affect the electrical currents, perhaps causing the affection to launch beating out of rhythm or yet control beating. In contrast, reducing the cholesterol normalized the structures underlying the electrical activity, thus promoting a general and healthy heartbeat.
Merck Sharp & Dohme Limited (MSD) announced the UK depart of 'Tredaptive'® (nicotinic acid/laropiprant) 1000 mg/20 mg (two tablets once diurnal maintenance dose), a new treatment possibility for dyslipidaemia. It is indicated for patients with combined mixed dyslipidaemia or primary hypercholesterolaemia and should be used in combination with a statin when the cholesterol lowering effect of statin monotherapy is inadequate, or as monotherapy when statins are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments, such as operate and weight loss, should endure during therapy. Treatment with statins has represented a better advance in lipid management which can provide a relative reduction in cardiovascular disease (CVD) risk of on all sides of 30% (versus placebo).
PTS, Inc. Hails New Announce Linking Alpine Cholesterol Levels To Increased Risk For Developing Alzheimer's Disease Or Vascular Dementia
Polymer Technology Systems, Inc. (PTS, Inc.), manufacturer of the CardioChek® PA point-of-care instrument and the CardioChek® internal cholesterol analyzer, released a statement hailing the latest study by Kaiser Permanente that suggests giant cholesterol levels are a heavy risk stuff for developing dementia and Alzheimer's Disease (AD) later in life. The results of the read were published in the journal Dementia & Geriatric Cognitive Disorders. The analysis study tracked 9, 844 men and women for four decades, starting when the participants were between 40 and 45. After controlling for weight, hypertension and diabetes, researchers discovered a significant link between borderline-high cholesterol and dementia.